EMEA prepares for pandemic vaccines
The European Medicines Agency (EMEA) hosted a meeting with its European Union member states' national counterparts, the European Commission, the European Center for Disease Prevention and Control (ECDC), the World Health Organization, the European Directorate for the Quality of Medicines and Healthcare (EDQM) and the European Vaccines Manufacturers. The purpose of the meeting was to share information on the novel influenza virus (swine flu; Marketletter May 4), as well as to discuss regulatory and scientific issues concerning the development and eventual approval of vaccines for use in a pandemic situation.
The EMEA stressed that "any decision on a strategy for development of pandemic vaccines will depend on recommendations from the WHO." The Agency noted that it has been preparing for a pandemic scenario since 2004, with the concern of a different strain of avian influenza, H5N1, which has caused over 250 deaths worldwide, 115 of them in Indonesia (Marketletters passim).
Four drugs approved to be modified for pandemic vaccine use
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze